Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.46 |
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24967302 | 0.91 | BRD4 (0.44) | BRD4FAAHPDE2AMAPK1BRD2 | |
| SCHEMBL24967296 | 0.89 | BRD4 (0.40) | BRD4FAAHPDE2AMAPK1BRD2 | |
| SCHEMBL24966149 | 0.87 | BRD4 (0.39) | BRD4FAAHPDE2AMAPK1BRD2 | |
| SCHEMBL24966150 | 0.87 | BRD4 (0.44) | BRD4FAAHPDE2AMAPK1BRD2 | |
| SCHEMBL24966158 | 0.83 | BRD4 (0.53) | BRD4FAAHMAPK1BRD2BRD3 | |
| SCHEMBL24966204 | 0.81 | BRD4 (0.52) | BRD4FAAHMAPK1BRD2BRD3 | |
| SCHEMBL24967300 | 0.81 | BRD4 (0.47) | BRD4FAAHPDE2AMAPK1BRD2 | |
| SCHEMBL24966699 | 0.80 | BRD4 (0.46) | BRD4FAAHPDE2AMAPK1BRD2 | |
| SCHEMBL24966203 | 0.80 | BRD4 (0.42) | BRD4FAAHMAPK1BRD2BRD3 | |
| SCHEMBL24966157 | 0.79 | BRD4 (0.45) | BRD4FAAHMAPK1BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021068943-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | 成都麻沸散医药科技有限公司 | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CYP21A2, CYP11B1, CYP11B2 | BRD4 2260/4885FAAH 291/4885PDE2A 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.